Patricia Murphy1, Sergei Likhodii, Kirk Nylen, W M Burnham. 1. Department of Pharmacology, The University of Toronto, Medical Sciences Building, 1 King's College Circle, Toronto, Ontario, Canada M5S 1A8. pattyannemurphy@hotmail.com
Abstract
BACKGROUND: The ketogenic diet is used to treat epilepsy refractory to anticonvulsant medication. Individuals with epilepsy often have behavioral problems and deficits in attention and cognitive functioning. The ketogenic diet has been found to effect improvements in these domains. It has also been suggested that the ketogenic diet may act as a mood stabilizer. METHODS: The present research used the Porsolt test, an animal model of depression, to determine whether the ketogenic diet has antidepressant properties. Porsolt test scores of rats on the ketogenic diet were compared with those of rats on a control diet. RESULTS: The rats on the ketogenic diet spent less time immobile, suggesting that rats on the ketogenic diet, like rats treated with antidepressants, are less likely to exhibit "behavioral despair." CONCLUSIONS: It is concluded that the ketogenic diet may have antidepressant properties.
BACKGROUND: The ketogenic diet is used to treat epilepsy refractory to anticonvulsant medication. Individuals with epilepsy often have behavioral problems and deficits in attention and cognitive functioning. The ketogenic diet has been found to effect improvements in these domains. It has also been suggested that the ketogenic diet may act as a mood stabilizer. METHODS: The present research used the Porsolt test, an animal model of depression, to determine whether the ketogenic diet has antidepressant properties. Porsolt test scores of rats on the ketogenic diet were compared with those of rats on a control diet. RESULTS: The rats on the ketogenic diet spent less time immobile, suggesting that rats on the ketogenic diet, like rats treated with antidepressants, are less likely to exhibit "behavioral despair." CONCLUSIONS: It is concluded that the ketogenic diet may have antidepressant properties.
Authors: John M Scichilone; Kalyan Yarraguntla; Ana Charalambides; Jacob P Harney; David Butler Journal: J Mol Neurosci Date: 2016-04-25 Impact factor: 3.444
Authors: Pamela R Westmark; Alejandra Gutierrez; Aaron K Gholston; Taralyn M Wilmer; Cara J Westmark Journal: Neurochem Int Date: 2020-01-17 Impact factor: 3.921
Authors: Tomasz Żarnowski; Tomasz Chorągiewicz; Maria Tulidowicz-Bielak; Sebastian Thaler; Robert Rejdak; Iwona Żarnowski; Waldemar Andrzej Turski; Maciej Gasior Journal: J Neural Transm (Vienna) Date: 2011-12-27 Impact factor: 3.575